Cytokinetics (CYTK) Reports Licensing Collaboration & Royalty Monetization Deals with RTW Investments Focused to CK-3773274, Next-Generation Cardiac Myosin Inhibitor

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. GOOGL
6. APGE
7. ABBV
8. USO
9. MSFT
10. IBM

Go back to Cytokinetics (CYTK) Reports Licensing Collaboration & Royalty Monetization Deals with RTW Investments Focused to CK-3773274, Next-Generation Cardiac Myosin Inhibitor

Cytokinetics Announces Licensing Collaboration and Royalty Monetization Deals with RTW Investments Focused to CK-3773274, Next-Generation Cardiac Myosin Inhibitor

July 14, 2020 7:30 AM EDT

$250 Million in Committed Capital to Cytokinetics;Additional $200 Million in Development and Commercialization Milestone Payments

Ji Xing Pharmaceuticals to Develop & Commercialize in China

RTW Provides Access to Capital to Cytokinetics to Fund Global Development in Exchange for Potential Royalties and Agrees to Purchase Royalty on Mavacamten

Company to Host Conference Call and Webcast Today at 8:30 am Eastern Time

... More